Drug Trial Radar · NCT07108699
Evaluation of the Safety and Efficacy of HSK39004 Dry Powder Inhaler in Chinese Patients With Chronic Obstructive Pulmonary Disease (COPD)
Last checked: Nov 20, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Aug 13, 2025
Primary completion
Aug 30, 2026
Study completion Sep 30, 2026
Sponsor
- Lead sponsor
- Haisco Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety and efficacy of the HSK39004 Dry Powder Inhaler compared with the placebo in the treatment of Chinese patients with COPD.
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
HSK39004 Dry Powder Inhaler-0.75mgDrug
HSK39004 Dry Powder Inhaler: Inhale through the mouth, 0.75mg each time, twice a day
HSK39004 Dry Powder Inhaler-1.5mgDrug
HSK39004 Dry Powder Inhaler: Inhale through the mouth, 1.5mg each time, twice a day
HSK39004 Dry Powder Inhaler SimulantDrug
HSK39004 Dry Powder Inhaler Simulants, administered via oral inhalation, 1 tablet each time, twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- The ΔFEV1 AUC0-12h after the 4th week administration (the area under the curve representing the change in FEV1 from baseline to 12 hours after administration)Time frame: Week 4
Locations
1 site in 1 country. Site status is shown where the registry gives one.
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.